Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132243 | 0.98 | TSHR (0.32) | THRBBLMPMP22KMT2ATSHR | |
| Fluoride SCHEMBL22206791 | 0.96 | TSHR (0.32) | THRBBLMPMP22KMT2ATSHR | |
| Bromide SCHEMBL22206792 | 0.96 | TSHR (0.32) | THRBBLMPMP22KMT2ATSHR | |
| Acetic Acid SCHEMBL2788321 | 0.93 | TSHR (0.33) | THRBBLMPMP22KMT2ATSHR | |
| Cyanide SCHEMBL22191188 | 0.93 | TSHR (0.30) | TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL22206793 | 0.91 | PARP1 (0.30) | — | |
| SCHEMBL29082836 | 0.90 | — | — | |
| SCHEMBL29082823 | 0.88 | — | — | |
| SCHEMBL22190612 | 0.85 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL5673706 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025098826-A1 | A METHOD OF TREATING SKIN | UNILEVER IP HOLDINGS B.V. (NL) | 2025-05-15 | — | — | WO | claimed |
| CN-119280089-A | Stabilization of intermediate diphenol compounds in cosmetic compositions | 联合利华知识产权控股有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-114206298-B | Stabilization of intermediate diphenol compounds in cosmetic compositions | 联合利华知识产权控股有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-115484921-B | Cosmetic compositions stabilized in N, N' -diacetyl cystine | 联合利华知识产权控股有限公司 | 2024-10-18 | — | — | CN | claimed |
| EP-3996664-B1 | STABILIZATION OF RESORCINOL COMPOUNDS IN COSMETIC COMPOSITIONS | UNILEVER GLOBAL IP LTD (GB) | 2024-08-21 | — | — | EP | claimed |
| US-20240050342-A1 | PROLIPID COMPOSITION FOR PERSONALIZED BENEFITS AND METHOD FOR USING THE SAME | CONOPCO, INC., D/B/A UNILEVER (US) | 2024-02-15 | — | — | US | claimed |
| EP-4267255-A1 | PROLIPID COMPOSITION FOR PERSONALIZED BENEFITS AND METHOD FOR USING THE SAME | Unilever IP Holdings B.V. (NL) | 2023-11-01 | — | — | EP | claimed |
| EP-4142680-B1 | STABILIZED COSMETIC COMPOSITIONS WITH N, N'-DI-ACETYL CYSTINE | UNILEVER IP HOLDINGS B V (NL) | 2023-10-18 | — | — | EP | claimed |
| EP-3484475-B1 | 1-METHYLNICOTINAMIDE FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | PHARMENA S A (PL) | 2023-09-27 | — | — | EP | claimed |
| CN-116723822-A | Prolipid compositions providing personalized benefits and methods of use thereof | 联合利华知识产权控股有限公司 | 2023-09-08 | — | — | CN | claimed |
| EP-2026651-A2 | COMBINATION THERAPY WITH NON-SELECTIVE COX INHIBITORS TO PREVENT COX-RELATED GASTRIC INJURIES | PHARMENA NORTH AMERICA INC. (CA) | 2009-02-25 | — | — | EP | claimed |
| WO-2008062324-A2 | COMPOSITIONS COMPRISING NICOTINAMIDE AND WAKAME EXTRACT HAVING SKIN ANTI-AGING PROPERTIES | DERMENA (CA) | 2008-05-29 | — | — | WO | claimed |
| EP-1919466-A2 | FORMULATIONS FOR TREATMENT OF LIPOPROTEIN ABNORMALITIES COMPRISING A STATIN AND A METHYLNICOTINAMIDE DERIVATIVE | PHARMENA NORTH AMERICA INC. (CA) | 2008-05-14 | — | — | EP | claimed |
| US-20070259861-A1 | Combination therapy with non-selective COX inhibitors to prevent COX-related gastric injuries | PHARMENA NORTH AMERICA INC. (CA) | 2007-11-08 | — | — | US | claimed |
| WO-2007103540-A2 | COMBINATION THERAPY WITH NON-SELECTIVE COX INHIBITORS TO PREVENT COX-RELATED GASTRIC INJURIES | PHARMENA NORTH AMERICA INC. (CA) | 2007-09-13 | — | — | WO | claimed |
| WO-2007074406-A2 | FORMULATIONS FOR TREATMENT OF LIPOPROTEIN ABNORMALITIES COMPRISING A STATIN A STATIN AND A METHYLNICOTINAMIDE DERIVATIVE | PHARMENA NORTH AMERICA INC. (CA) | 2007-07-05 | — | — | WO | claimed |
| US-20070021379-A1 | Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities | PHARMENA NORTH AMERICA INC. (CA) | 2007-01-25 | — | — | US | claimed |
| EP-1147086-B1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | TECHNICAL UNIVERSITY OF LODZ (PL) | 2005-03-30 | — | — | EP | claimed |
| EP-1147086-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | Technical University of Lodz (PL) | 2001-10-24 | — | — | EP | claimed |
| WO-2000040559-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | TECHNICAL UNIVERSITY OF LODZ (PL) | 2000-07-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259861-A1 | Combination therapy with non-selective COX inhibitors to prevent COX-related gastric injuries | PTGS1, PTGS2, PTGES2 | THRB 3583/4885BLM 4156/4885PMP22 4393/4885 |
| US-20070021379-A1 | Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities | HMGCR, NAMPT, NNMT | THRB 2392/4885BLM 4094/4885PMP22 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.